198 related articles for article (PubMed ID: 34861695)
1. An engineered activated factor V for the prevention and treatment of acute traumatic coagulopathy and bleeding in mice.
Joseph BC; Miyazawa BY; Esmon CT; Cohen MJ; von Drygalski A; Mosnier LO
Blood Adv; 2022 Feb; 6(3):959-969. PubMed ID: 34861695
[TBL] [Abstract][Full Text] [Related]
2. An engineered factor Va prevents bleeding induced by anticoagulant wt activated protein C.
von Drygalski A; Bhat V; Gale AJ; Burnier L; Cramer TJ; Griffin JH; Mosnier LO
PLoS One; 2014; 9(8):e104304. PubMed ID: 25127130
[TBL] [Abstract][Full Text] [Related]
3. An engineered factor Va prevents bleeding induced by direct-acting oral anticoagulants by different mechanisms.
von Drygalski A; Bhat V; Gale AJ; Averell PM; Cramer TJ; Elias DJ; Griffin JH; Mosnier LO
Blood Adv; 2020 Aug; 4(15):3716-3727. PubMed ID: 32777068
[TBL] [Abstract][Full Text] [Related]
4. Improved coagulation and haemostasis in haemophilia with inhibitors by combinations of superFactor Va and Factor VIIa.
Bhat V; von Drygalski A; Gale AJ; Griffin JH; Mosnier LO
Thromb Haemost; 2016 Mar; 115(3):551-61. PubMed ID: 26466980
[TBL] [Abstract][Full Text] [Related]
5. Improved hemostasis in hemophilia mice by means of an engineered factor Va mutant.
von Drygalski A; Cramer TJ; Bhat V; Griffin JH; Gale AJ; Mosnier LO
J Thromb Haemost; 2014; 12(3):363-72. PubMed ID: 24818532
[TBL] [Abstract][Full Text] [Related]
6. Comparative response of platelet fV and plasma fV to activated protein C and relevance to a model of acute traumatic coagulopathy.
Campbell JE; Meledeo MA; Cap AP
PLoS One; 2014; 9(6):e99181. PubMed ID: 24921658
[TBL] [Abstract][Full Text] [Related]
7. Clinical and mechanistic drivers of acute traumatic coagulopathy.
Cohen MJ; Kutcher M; Redick B; Nelson M; Call M; Knudson MM; Schreiber MA; Bulger EM; Muskat P; Alarcon LH; Myers JG; Rahbar MH; Brasel KJ; Phelan HA; del Junco DJ; Fox EE; Wade CE; Holcomb JB; Cotton BA; Matijevic N;
J Trauma Acute Care Surg; 2013 Jul; 75(1 Suppl 1):S40-7. PubMed ID: 23778510
[TBL] [Abstract][Full Text] [Related]
8. Factor V is an anticoagulant cofactor for activated protein C during inactivation of factor Va.
Cramer TJ; Griffin JH; Gale AJ
Pathophysiol Haemost Thromb; 2010; 37(1):17-23. PubMed ID: 20501981
[TBL] [Abstract][Full Text] [Related]
9. Assessing Factor V Antigen and Degradation Products in Burn and Trauma Patients.
Keyloun JW; Le TD; Orfeo T; Brummel-Ziedins KE; Bravo MC; Kaye MD; Bourne DE; Carney BC; Freeman K; Mann KG; Pusateri AE; Shupp JW;
J Surg Res; 2022 Jun; 274():169-177. PubMed ID: 35180493
[TBL] [Abstract][Full Text] [Related]
10. "In vitro" correction of the severe factor V deficiency-related coagulopathy by a novel plasma-derived factor V concentrate.
Bulato C; Novembrino C; Anzoletti MB; Spiezia L; Gavasso S; Berbenni C; Tagariello G; Farina C; Nardini I; Campello E; Peyvandi F; Simioni P
Haemophilia; 2018 Jul; 24(4):648-656. PubMed ID: 29578313
[TBL] [Abstract][Full Text] [Related]
11. Modulation of the activated protein C pathway in severe haemophilia A patients: The effects of thrombomodulin and a factor V-stabilizing fab.
Brophy DF; Martin EJ; Mohammed BM; Barrett JC; Kuhn JG; Nolte ME; Wiinberg B; Holmberg HL; Lund J; Salbo R; Waters EK
Haemophilia; 2017 Nov; 23(6):941-947. PubMed ID: 28750471
[TBL] [Abstract][Full Text] [Related]
12. New considerations on pathways involved in acute traumatic coagulopathy: the thrombin generation paradox.
Gangloff C; Mingant F; Theron M; Galinat H; Grimault O; Ozier Y; Pichavant-Rafini K
World J Emerg Surg; 2019; 14():57. PubMed ID: 31857822
[TBL] [Abstract][Full Text] [Related]
13. A prospective observational study of acute traumatic coagulopathy in traumatic bleeding from the battlefield.
Woolley T; Gwyther R; Parmar K; Kirkman E; Watts S; Midwinter M; Lucca JD; Hunt BJ
Transfusion; 2020 Jun; 60 Suppl 3():S52-S61. PubMed ID: 32478880
[TBL] [Abstract][Full Text] [Related]
14. Emicizumab-mediated haemostatic function in patients with haemophilia A is down-regulated by activated protein C through inactivation of activated factor V.
Yada K; Nogami K; Shinozawa K; Kitazawa T; Hattori K; Amano K; Fukutake K; Shima M
Br J Haematol; 2018 Oct; 183(2):257-266. PubMed ID: 30125997
[TBL] [Abstract][Full Text] [Related]
15. An increased tendency in fibrinogen activity and its association with a hypo-fibrinolytic state in early stages after injury in patients without acute traumatic coagulopathy (ATC).
He S; Blombäck M; Boström F; Wallen H; Svensson J; Östlund A
J Thromb Thrombolysis; 2018 May; 45(4):477-485. PubMed ID: 29564685
[TBL] [Abstract][Full Text] [Related]
16. The tissue factor pathway mediates both activation of coagulation and coagulopathy after injury.
Howard BM; Miyazawa BY; Dong W; Cedron WJ; Vilardi RF; Ruf W; Cohen MJ
J Trauma Acute Care Surg; 2015 Dec; 79(6):1009-13; discussion 1014. PubMed ID: 26317815
[TBL] [Abstract][Full Text] [Related]
17. Importance of individual activated protein C cleavage site regions in coagulation factor V for factor Va inactivation and for factor Xa activation.
Heeb MJ; Rehemtulla A; Moussalli M; Kojima Y; Kaufman RJ
Eur J Biochem; 1999 Feb; 260(1):64-75. PubMed ID: 10091585
[TBL] [Abstract][Full Text] [Related]
18. Functional properties of factor V and factor Va encoded by the R2-gene.
Hoekema L; Castoldi E; Tans G; Girelli D; Gemmati D; Bernardi F; Rosing J
Thromb Haemost; 2001 Jan; 85(1):75-81. PubMed ID: 11204592
[TBL] [Abstract][Full Text] [Related]
19. Intravenous administration of mesenchymal stromal cells leads to a dose-dependent coagulopathy and is unable to attenuate acute traumatic coagulopathy in rats.
Wu X; Darlington DN; Christy BA; Liu B; Keesee JD; Salgado CL; Bynum JA; Cap AP
J Trauma Acute Care Surg; 2022 Mar; 92(3):542-552. PubMed ID: 34797814
[TBL] [Abstract][Full Text] [Related]
20. Traumatic coagulopathy--part 1: Pathophysiology and diagnosis.
Palmer L; Martin L
J Vet Emerg Crit Care (San Antonio); 2014; 24(1):63-74. PubMed ID: 24382014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
